 "Strong triggers for Strides Shasun")
Pharmaceutical major Strides Pharma Science posted a pre-tax loss of Rs 217.8 crore for the fourth quarter ended March 31, 2020, over the withdrawal of its flagship Ranitidine product Zantac from the US market on the last day of FY20. It had posted a pre-tax profit of Rs 51.9 crore in the corresponding period of the previous fiscal.
The Bengaluru-headquartered company posted a consolidated loss of Rs 206.5 crore for the March quarter because of the Ranitidine setback, while consolidated revenue for the quarter reported a flat growth at Rs 636.2 crore.
“We are satisfied that the regulated markets continued
